Press Room - Sanofi US News
Oct 26, 2023 · Sanofi Beyfortus™ (nirsevimab-alip) Statement. Updated as of October 26, 2023. There has been unprecedented demand for Beyfortus™ (nirsevimab-alip). For the first time in history, health care providers are able to help protect an extraordinary number of infants against respiratory syncytial virus (RSV) disease.
Sanofi shipping BEYFORTUS® in US to help protect ... - news.sanofi…
Sep 16, 2024 · BEYFORTUS is a single-dose long-acting antibody designed to help prevent RSV LRTD in infants through 5 months, the length of the typical RSV season in the US. For children undergoing cardiac surgery with cardiopulmonary bypass, an additional dose of BEYFORTUS is recommended as soon as the child is stable after surgery.
AZ, Sanofi’s Beyfortus cleared in China for RSV prevention
Jan 2, 2024 · AstraZeneca and Sanofi’s long-acting antibody Beyfortus has been approved in China for the prevention of respiratory syncytial virus (RSV) infections in newborns and infants, opening up a major...
Beyfortus® immunization to protect infants from RSV has begun
Oct 28, 2024 · Beyfortus ® is the first immunization designed for all infants to help prevent RSV lower respiratory tract disease through their first RSV season. Beyfortus ® is also indicated for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
Sanofi shipping BEYFORTUS® in US to help protect babies …
Sep 16, 2024 · BEYFORTUS is a single-dose long-acting antibody designed to help prevent RSV LRTD in infants through 5 months, the length of the typical RSV season in the US. For children undergoing cardiac...
FDA Approves New Drug to Prevent RSV in Babies and Toddlers
Today, the U.S. Food and Drug Administration approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants...
AZ, Sanofi get first green light for RSV prophylactic antibody
Nov 5, 2024 · AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections.
Sanofi Beyfortus™ (nirsevimab-alip) Injection Update
Dec 14, 2023 · Sanofi Beyfortus™ (nirsevimab-alip) Injection Update. Sanofi and our partner AstraZeneca continue to engage with government officials, healthcare providers and others in the U.S. regarding supply of Beyfortus™ (nirsevimab-alip) 50mg and 100mg Injection.
Health Canada approves BEYFORTUS™ (nirsevimab) for the …
Apr 24, 2023 · BEYFORTUS™, an immunizing agent and a long-acting antibody designed for all infants for protection against LRTD from birth through their first RSV season with a single dose, is developed jointly by Sanofi and AstraZeneca.
Beyfortus approved in the US for the prevention of RSV lower ...
Jul 17, 2023 · AstraZeneca and Sanofi’s Beyfortus (nirsevimab) has been approved in the US for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their ...
- Some results have been removed